Department of Neurology, Chungnam National University Hospital, Daejeon, Korea
Multiple sclerosis (MS) is a demyelinating and inflammatory disease of the central nervous system.
Most patients develop MS in the form of relapsing-remitting multiple sclerosis (RRMS). Patients with RRMS also develop neurological deficits over time and progress to secondary progressive MS. A mi- nority of patients develop primary progressive MS, which shows a progressive clinical course from the initial phase of the disease. Development of disease modifying therapies has been focused on
RRMS and treatment for progressive MS (secondary progressive multiple sclerosis and primary pro-
gressive multiple sclerosis) has been limited. There have been many advances in progressive MS
treatment in recent years. This review summarizes recent therapeutic research and explores the neurofilament light chain, which is drawing attention as a biomarker.
Journal of Multiple Sclerosis 10(2):27-31, 2019
